Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study

Clinical Neuropharmacology
Marta MaschioFrancesco Marchesi

Abstract

Polyneuropathy (PN) is a frequent and significant clinical manifestation of multiple myeloma that may be observed at onset of disease or induced during treatment as a therapy-related complication. Polyneuropathy may be a relevant issue in myeloma patients owing to its significant impact on the quality of life, considering that it may lead to dose reduction or treatment discontinuation. The present retrospective study intended to evaluate efficacy of pregabalin (PGB) in treatment of PN in multiple myeloma patients. Medical charts of 108 consecutive PN myeloma patients were reviewed. Data regarding the tumor history and therapy as well as the clinical and neurophysiological examinations 6 months before and after initiation of PGB therapy were collected. Thirty-eight medical charts had all the requested information. All patients (n = 38) underwent bortezomib-based treatment; 19 were previously treated and 19 were treatment naive. At first neurologic visit, all patients had PN symptoms (grade 2 of National Cancer Institute-Common Toxicity Criteria) without relevant pain. Neurophysiological evaluation showed a significant decrease in sensory nerve action potential amplitude (P = 0.006), conduction velocity (P = 0.006), and distal la...Continue Reading

References

Jun 1, 1976·Pain·J Scott, E C Huskisson
Jul 25, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T J Postma, J J Heimans
Aug 7, 2003·Seminars in Radiation Oncology·Andy TrottiPhilip Rubin
Dec 15, 2006·Lancet Neurology·Jean-Christophe Antoine, Jean-Philippe Camdessanché
Mar 19, 2008·Journal of the Peripheral Nervous System : JPNS·Anthony J Windebank, Wolfgang Grisold
Feb 5, 2009·Journal of the Peripheral Nervous System : JPNS·Francesca LanzaniGuido Cavaletti
Oct 12, 2010·The Lancet Oncology·Michel DelforgePieter Sonneveld
Jan 18, 2011·Hematology·Pieter Sonneveld, Joost L M Jongen
Apr 27, 2011·British Journal of Haematology·John A SnowdenUNKNOWN Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum
Aug 5, 2011·Clinical Pharmacology and Therapeutics·D R PachmanC L Loprinzi
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CavalettiW Grisold
Aug 27, 2013·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Saiko NasuSatoshi Kuwabara
Mar 5, 2014·CA: a Cancer Journal for Clinicians·Susanna B ParkMatthew C Kiernan
Apr 16, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dawn L HershmanCharles L Loprinzi
Nov 18, 2014·Hematological Oncology·Marta MorawskaMarek Hus
Dec 6, 2014·Pain Research & Management : the Journal of the Canadian Pain Society = Journal De La Société Canadienne Pour Le Traitement De La Douleur·Dwight MoulinUNKNOWN Canadian Pain Society
Jul 15, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Shivani S ShindeCharles L Loprinzi
Oct 4, 2015·Haematologica·Evangelos TerposUNKNOWN European Myeloma Network
Dec 5, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·A J M BeijersF Mols
Dec 18, 2015·The Review of Diabetic Studies : RDS·Saad JavedRayaz A Malik
Mar 11, 2016·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·C LeoneA Truini
Oct 6, 2016·Journal of Multidisciplinary Healthcare·Theresa Mallick-SearleJeannine M Brant
Feb 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CavalettiW Grisold

❮ Previous
Next ❯

Related Concepts

Related Feeds

Axonal Neuropathies

Axonal Neuropathy refers to disease or dysfunction of nerves caused as a result of damage or degeneration of axons. Here is the latest research.